---
title: "创新药板块反弹窗口开启：从「炒预期」到「看兑现」，生物科技 ETF 或迎来配置视窗"
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/40308318.md"
description: "一、CXO 龍頭業績超預期，板塊情緒顯著提振 4 月 27 日晚間，CXO 龍頭葯明康得（603259.SH/2359.HK）發佈 2026 年一季度業績，多項指標大超市場預期：• 營收首次突破百億：Q1 實現營業收入 124.36 億元，同比增長 28.81%，其中持續經營業務收入同比強勁增長 39.4%• 盈利能力創歷史新高：經調整 Non-IFRS 歸母凈利潤 46.0 億元..."
datetime: "2026-04-30T02:05:32.000Z"
locales:
  - [en](https://longbridge.com/en/topics/40308318.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/40308318.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/40308318.md)
author: "[華夏基金香港](https://longbridge.com/en/profiles/26497709.md)"
---

# 创新药板块反弹窗口开启：从「炒预期」到「看兑现」，生物科技 ETF 或迎来配置视窗

**1\. CXO Leader's Earnings Exceed Expectations, Boosting Sector Sentiment**

On the evening of April 27th, WuXi AppTec (603259.SH/2359.HK), a leading CXO company, released its Q1 2026 earnings report, with multiple indicators significantly exceeding market expectations:

• Revenue Surpassed 10 Billion for the First Time: Q1 operating revenue reached 12.436 billion yuan, a year-on-year increase of 28.81%, with revenue from continuing operations growing strongly by 39.4% YoY.

• Profitability Reached a Record High: Adjusted Non-IFRS net profit attributable to shareholders was 4.60 billion yuan, a substantial increase of 71.7% YoY; Non-GAAP net profit attributable to shareholders was 4.28 billion yuan, up 83.6% YoY.

• Gross Margin Exceeded 50%: Adjusted Non-IFRS gross margin improved to 50.4%, and net profit margin attributable to shareholders reached 37.0%, both setting new historical highs.

• Backlog of Nearly 60 Billion: The backlog for continuing operations reached 59.77 billion yuan, a 23.6% increase YoY, indicating very high earnings visibility.

Driven by the strong earnings, WuXi AppTec's A-shares hit the daily limit up, while its Hong Kong shares surged over 16% intraday (closing the morning session up approximately 14.92%-15.79%). This also lifted other CXO stocks like WuXi XDC and WuXi Biologics, significantly improving sentiment in the biotech sector.

### Related Stocks

- [02359.HK](https://longbridge.com/en/quote/02359.HK.md)
- [603259.CN](https://longbridge.com/en/quote/603259.CN.md)
- [09926.HK](https://longbridge.com/en/quote/09926.HK.md)
- [02268.HK](https://longbridge.com/en/quote/02268.HK.md)
- [02269.HK](https://longbridge.com/en/quote/02269.HK.md)
- [WXXWY.US](https://longbridge.com/en/quote/WXXWY.US.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)
- [MSFT.US](https://longbridge.com/en/quote/MSFT.US.md)
- [GOOG.US](https://longbridge.com/en/quote/GOOG.US.md)
- [GOOGL.US](https://longbridge.com/en/quote/GOOGL.US.md)
- [INTC.US](https://longbridge.com/en/quote/INTC.US.md)
- [04335.HK](https://longbridge.com/en/quote/04335.HK.md)
- [META.US](https://longbridge.com/en/quote/META.US.md)
- [C-R.US](https://longbridge.com/en/quote/C-R.US.md)